Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yuekang Huoxin Pill after DCB for coronary heart disease
ChiCTR2100051859Phase 4Recruiting
- Sponsor
- Fuwai Hospital
- Start
- Jan 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Huoxin Pill in coronary arteriosclerosis (2 arms), sponsored by Fuwai Hospital. Primary endpoint: Quantitative flow ratio at 12-month postoperative follow-up. Started Jan 2022; status: recruiting.
02
Drugs
Huoxin Pill
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100051859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051859.